神经化学性痴呆诊断的国际质量控制调查

International quality control survey of neurochemical dementia diagnostics.

作者信息

Lewczuk Piotr, Beck Georg, Ganslandt Oliver, Esselmann Hermann, Deisenhammer Florian, Regeniter Axel, Petereit Hela-Felicitas, Tumani Hayrettin, Gerritzen Andreas, Oschmann Patrick, Schröder Johannes, Schönknecht Peter, Zimmermann Klaus, Hampel Harald, Bürger Katharina, Otto Markus, Haustein Sabine, Herzog Karin, Dannenberg Rainer, Wurster Ulrich, Bibl Mirko, Maler Juan Manuel, Reubach Udo, Kornhuber Johannes, Wiltfang Jens

机构信息

Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.

出版信息

Neurosci Lett. 2006 Nov 27;409(1):1-4. doi: 10.1016/j.neulet.2006.07.009. Epub 2006 Oct 11.

DOI:10.1016/j.neulet.2006.07.009

PMID:17045397

Abstract

UNLABELLED

Currently, neurochemical dementia diagnostics (NDD) are increasingly entering routine clinical neurochemistry, offering improved early and differential diagnosis of dementias. However, there is an obvious lack of standardization in pre-analytical sample handling and systematic quality surveys. Therefore, in this study, 14 laboratories in Germany, Austria, and Switzerland were given aliquots of a human cerebrospinal fluid (CSF) sample, and were asked to measure Alzheimer's disease (AD) biomarkers (amyloid beta (Abeta) peptides, total Tau protein, and phosphorylated Tau protein (P-tau(181P))) according to their routine protocols.

RESULTS

The inter-laboratory coefficients of variation of the results obtained by the laboratories participating in this study were in the range of 20-30%. Although the results of this quality control survey are promising, the quality of measurements has to be further optimized.

摘要

未标注

目前，神经化学痴呆诊断（NDD）正越来越多地进入常规临床神经化学领域，为痴呆症提供了更好的早期诊断和鉴别诊断。然而，在分析前样本处理和系统质量调查方面明显缺乏标准化。因此，在本研究中，德国、奥地利和瑞士的14个实验室收到了一份人类脑脊液（CSF）样本的等分试样，并被要求根据其常规方案测量阿尔茨海默病（AD）生物标志物（淀粉样β（Aβ）肽、总 Tau 蛋白和磷酸化 Tau 蛋白（P-tau(181P)））。